Zobrazeno 1 - 10
of 35
pro vyhledávání: '"J. E. Marshall"'
Autor:
Franziska Heckel, Anna H. Turaj, Hayden Fisher, H. T. Claude Chan, Michael J. E. Marshall, Osman Dadas, Christine A. Penfold, Tatyana Inzhelevskaya, C. Ian Mockridge, Diego Alvarado, Ivo Tews, Tibor Keler, Stephen A. Beers, Mark S. Cragg, Sean H. Lim
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-15 (2022)
Agonistic CD27 monoclonal antibodies can be used to enhance the efficacy of depleting antibodies such as anti-CTLA-4 in a colon adenocarcinoma tumour model. CD27 antibody agonism is dependent on isotype and epitope specificity.
Externí odkaz:
https://doaj.org/article/f7e2de2c168f4f2984754369dc482291
Autor:
Michael J. E. Marshall, Alexander Knaupp, Christian Spick, Ilker Koese, Maria Maier, Mark S. Cragg, Florian Cymer, Tilman Schlothauer
Publikováno v:
The Journal of Immunology. 210:1837-1848
The classical complement system represents a central effector mechanism of Abs initiated by the binding of C1q to target bound IgG. Human C1q contains six heterotrimeric globular head groups that mediate IgG interaction, resulting in an avidity-drive
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Therapeutic monoclonal antibodies (mAbs) have become one of the fastest growing classes of drugs in recent years and are approved for the treatment of a wide range of indications, from cancer to autoimmune disease. Perhaps the best studied target is
Externí odkaz:
https://doaj.org/article/611cc471955e4b839bfbd90f105ebd8e
Autor:
Franziska, Heckel, Anna H, Turaj, Hayden, Fisher, H T Claude, Chan, Michael J E, Marshall, Osman, Dadas, Christine A, Penfold, Tatyana, Inzhelevskaya, C Ian, Mockridge, Diego, Alvarado, Ivo, Tews, Tibor, Keler, Stephen A, Beers, Mark S, Cragg, Sean H, Lim
Publikováno v:
Communications biology. 5(1)
Agonistic CD27 monoclonal antibodies (mAb) have demonstrated impressive anti-tumour efficacy in multiple preclinical models but modest clinical responses. This might reflect current reagents delivering suboptimal CD27 agonism. Here, using a novel pan
Autor:
Kerry L. Cox, Robert J. Oldham, Adam Palazzo, Florian Limani, Michael J. E. Marshall, Christian R. Frey, Christian Klein, Randy Jones, Matthew J. Carter, Sylvia Herter, Marina Bacac, Mark S. Cragg, Anna H. Turaj, Laura Sue Grosmaire, Pablo Umana, Stacey Tannheimer
Publikováno v:
The Journal of Immunology Author Choice
Idelalisib is a highly selective oral inhibitor of PI3Kδ indicated for the treatment of patients with relapsed chronic lymphocytic leukemia in combination with rituximab. Despite additive clinical effects, previous studies have paradoxically demonst
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 1881
Over recent decades it has become increasingly apparent that malignant cells, including chronic lymphocytic leukemia (CLL) cells, do not exist in isolation. Rather they coalesce with numerous "normal" cells of the body and, in the case of CLL, inhabi
Autor:
Ruth R. French, Kirstie L. S. Cleary, Matthew J. Carter, Stephen A. Beers, Mark S. Cragg, Michael J. E. Marshall, Lekh N. Dahal
Publikováno v:
Methods in Molecular Biology ISBN: 9781493988754
Over recent decades it has become increasingly apparent that malignant cells, including chronic lymphocytic leukemia (CLL) cells, do not exist in isolation. Rather they coalesce with numerous "normal" cells of the body and, in the case of CLL, inhabi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02560de772844ca6f2bd01df0f1f79bc
https://doi.org/10.1007/978-1-4939-8876-1_14
https://doi.org/10.1007/978-1-4939-8876-1_14
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Frontiers in Immunology
Frontiers in Immunology
Therapeutic monoclonal antibodies (mAbs) have become one of the fastest growing classes of drugs in recent years and are approved for the treatment of a wide range of indications, from cancer to autoimmune disease. Perhaps the best studied target is
Publikováno v:
BioDrugs. 31(3)
Antibody-based therapeutics has emerged as a major tool in cancer treatment. Guided by the superb specificity of the antibody variable domain, it allows the precise targeting of tumour markers. Recently, eliciting cellular effector functions, mediate
Autor:
J. E. Marshall, R. D. Hocken
Publikováno v:
Optimal Control Applications and Methods. 3:211-219
Two control schemes are devised to minimize a quadratic cost functional associated with a time varying linear system, when the linear system forms part of a plant that may contain delays in both control and measurement. Control scheme (1) makes use o